Home > Publications database > Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial.
 
Journal Article (Letter) DKFZ-2025-02052
http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2025
Springer Nature London

Leukemia 39, 2816–2819 () [10.1038/s41375-025-02780-7]
 GO

Classification:

Note: 39, pages 2816–2819 (2025)
Contributing Institute(s):
  1. DKTK Koordinierungsstelle Freiburg (FR01)
Research Program(s):
  1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2025
Database coverage:
Medline ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database
 Record created 2025-10-09, last modified 2025-11-13
Similar records



Rate this document:

Rate this document:
1
2
3
4
5
 
(Not yet reviewed)
DKFZ :: Search :: Submit :: Personalize :: Help
Powered by Invenio 1.1.7-dirty
Maintained by zb.invenio@dkfz-heidelberg.de

Impressum | Data Privacy Policy